Lexicon Pharmaceuticals, Inc · The Woodlands, TX United States · (NASDAQ (GM): LXRX)
Company Description
Lexicon Pharmaceuticals works with some of the biggest words in the dictionary -- words like deoxyribonucleic acid. The drug development company is focused on a handful of candidates it has identified and tested with its gene knockout technology. Its leading candidates include LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome. Other products in its pipeline include potential treatments for rheumatoid arthritis, diabetes, and glaucoma. The company, which began as Lexicon Genetics, developed knockout mice -- mice whose DNA has been modified to disrupt, or "knock out" certain gene functions -- to study the potential effects of drugs on various genetic targets. To read the full description, subscribe now.
Lexicon Pharmaceuticals, Inc Reports
Key Lexicon Pharmaceuticals, Inc Financials
| Company Type | Public - NASDAQ (GM): LXRX Headquarters |
| Fiscal Year-End | December |
| 2009 Employees | 345 |
Lexicon Pharmaceuticals, Inc Executives
| Title | Name & Bio | Contact |
| Chairman | Samuel Barker | |
| President, CEO, and Director | Arthur Sands | |
| VP Finance and Accounting and Principal Financial Officer | James Tessmer |
